View Filing Data

Print Document View Excel Document

Cover Page - shares	3 Months Ended
Cover Page - shares	Mar. 31, 2020	Apr. 24, 2020
Cover [Abstract]
Document Type	10-Q
Document Transition Report	false
Document Quarterly Report	true
Amendment Flag	false
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity File Number	001-36569
Entity Registrant Name	LANTHEUS HOLDINGS, INC.
Entity Central Index Key	0001521036
Current Fiscal Year End Date	--12-31
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	35-2318913
Entity Address, Address Line One	331 Treble Cove Road
Entity Address, City or Town	North Billerica,
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01862
City Area Code	(978)
Local Phone Number	671-8001
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	LNTH
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		39,756,364

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 95,713	$ 92,919
Accounts receivable, net	44,883	43,529
Inventory	30,814	29,180
Other current assets	8,967	7,283
Total current assets	180,377	172,911
Property, plant and equipment, net	108,613	116,497
Intangibles, net	6,930	7,336
Goodwill	15,714	15,714
Deferred tax assets, net	70,454	71,834
Other long-term assets	22,037	21,627
Total assets	404,125	405,919
Current liabilities
Current portion of long-term debt and other borrowings	10,143	10,143
Accounts payable	18,980	18,608
Accrued expenses and other liabilities	32,836	37,360
Total current liabilities	61,959	66,111
Asset retirement obligations	13,243	12,883
Long-term debt, net and other borrowings	181,488	183,927
Other long-term liabilities	29,037	28,397
Total liabilities	285,727	291,318
Commitments and contingencies (See Note 15)
Stockholders’ equity
Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding)	0	0
Common stock ($0.01 par value, 250,000 shares authorized; 39,750 and 39,251 shares issued and outstanding, respectively)	398	393
Additional paid-in capital	253,530	251,641
Accumulated deficit	(133,136)	(136,473)
Accumulated other comprehensive loss	(2,394)	(960)
Total stockholders’ equity	118,398	114,601
Total liabilities and stockholders’ equity	$ 404,125	$ 405,919

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	25,000,000	25,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	39,750,000	39,251,000
Common stock, shares outstanding (in shares)	39,750,000	39,251,000

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Revenues	$ 90,704	$ 86,510
Cost of goods sold	52,702	42,426
Gross profit	38,002	44,084
Operating expenses
Sales and marketing	10,130	10,397
General and administrative	16,699	12,589
Research and development	4,048	4,929
Total operating expenses	30,877	27,915
Operating income	7,125	16,169
Interest expense	1,946	4,592
Other income	(350)	(1,187)
Income before income taxes	5,529	12,764
Income tax expense	2,192	2,815
Net income	$ 3,337	$ 9,949
Net income per common share:
Basic (in dollars per share)	$ 0.08	$ 0.26
Diluted (in dollars per share)	$ 0.08	$ 0.25
Weighted-average common shares outstanding:
Basic (in shares)	39,433	38,603
Diluted (in shares)	40,102	39,787

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement of Comprehensive Income [Abstract]
Net income	$ 3,337	$ 9,949
Other comprehensive (loss) income:
Foreign currency translation	(446)	56
Unrealized loss on cash flow hedges, net of tax	(988)	0
Total other comprehensive (loss) income	(1,434)	56
Comprehensive income	$ 1,903	$ 10,005

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2018		38,466
Beginning balance at Dec. 31, 2018	$ 71,002	$ 385	$ 239,865	$ (168,140)	$ (1,108)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	9,949			9,949
Other comprehensive income (loss)	56				56
Stock option exercises and employee stock plan purchases (in shares)		37
Stock option exercises and employee stock plan purchases	606	$ 0	606
Vesting of restricted stock awards and units (in shares)		365
Vesting of restricted stock awards and units	0	$ 4	(4)
Shares withheld to cover taxes (in shares)		(50)
Shares withheld to cover taxes	(1,120)	$ (1)	(1,119)
Stock-based compensation	2,720		2,720
Ending balance (in shares) at Mar. 31, 2019		38,818
Ending balance at Mar. 31, 2019	83,213	$ 388	242,068	(158,191)	(1,052)
Beginning balance (in shares) at Dec. 31, 2019		39,251
Beginning balance at Dec. 31, 2019	114,601	$ 393	251,641	(136,473)	(960)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	3,337			3,337
Other comprehensive income (loss)	(1,434)				(1,434)
Stock option exercises and employee stock plan purchases (in shares)		33
Stock option exercises and employee stock plan purchases	366		366
Vesting of restricted stock awards and units (in shares)		563
Vesting of restricted stock awards and units	0	$ 6	(6)
Shares withheld to cover taxes (in shares)		(97)
Shares withheld to cover taxes	(1,547)	$ (1)	(1,546)
Stock-based compensation	3,075		3,075
Ending balance (in shares) at Mar. 31, 2020		39,750
Ending balance at Mar. 31, 2020	$ 118,398	$ 398	$ 253,530	$ (133,136)	$ (2,394)

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating activities
Net income	$ 3,337	$ 9,949
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation, amortization and accretion	3,732	3,323
Impairment of long-lived assets	7,275	0
Amortization of debt related costs	169	320
Provision for bad debt	202	(190)
Provision for excess and obsolete inventory	449	511
Stock-based compensation	3,075	2,720
Deferred taxes	1,467	1,741
Long-term income tax receivable	(554)	(802)
Long-term income tax payable and other long-term liabilities	705	1,018
Other	452	(6)
Increases (decreases) in cash from operating assets and liabilities:
Accounts receivable	(1,750)	(1,040)
Inventory	(2,098)	465
Other current assets	1,149	(1,152)
Accounts payable	(913)	1,458
Accrued expenses and other liabilities	(7,289)	(7,847)
Net cash provided by operating activities	9,408	10,468
Investing activities
Capital expenditures	(2,698)	(10,550)
Net cash used in investing activities	(2,698)	(10,550)
Financing activities
Payments on long-term debt and other borrowings	(2,551)	(717)
Proceeds from stock option exercises	0	324
Proceeds from issuance of common stock	366	282
Payments for minimum statutory tax withholding related to net share settlement of equity awards	(1,547)	(1,120)
Net cash used in financing activities	(3,732)	(1,231)
Effect of foreign exchange rates on cash and cash equivalents	(184)	(27)
Net increase (decrease) in cash and cash equivalents	2,794	(1,340)
Cash and cash equivalents, beginning of period	92,919	113,401
Cash and cash equivalents, end of period	$ 95,713	$ 112,061

Basis of Presentation	3 Months Ended
Basis of Presentation	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Note Regarding Company References and Trademarks Unless the context otherwise requires, references to the “Company” and “Lantheus” refer to Lantheus Holdings, Inc. and its direct and indirect wholly-owned subsidiaries, references to “Holdings” refer to Lantheus Holdings, Inc. and not to any of its subsidiaries, and references to “LMI” refer to Lantheus Medical Imaging, Inc., the direct subsidiary of Holdings. Solely for convenience, the Company refers to trademarks, service marks and trade names without the TM, SM and ® symbols. Those references are not intended to indicate, in any way, that the Company will not assert, to the fullest extent permitted under applicable law, its rights to its trademarks, service marks and trade names. Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the accounts of Lantheus Holdings, Inc. and its direct and indirect wholly-owned subsidiaries and have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all of the information and notes required by generally accepted accounting principles in the United States of America (“U.S. GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement have been included. The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results that may be expected for the year ended December 31, 2020 or any future period. The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date but does not include all of the information and notes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities Exchange Commission (“SEC”) on February 25, 2020. Progenics Transaction On October 1, 2019, the Company entered into an Agreement and Plan of Merger (the “Initial Merger Agreement”) to acquire Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) (“Progenics” and, such acquisition, the “Progenics Transaction”). The terms of the Initial Merger Agreement were amended and restated on February 20, 2020 (the “Amended Merger Agreement”). Progenics is an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer. Under the terms of the Amended Merger Agreement, the Company will acquire all of the issued and outstanding shares of Progenics common stock by means of a merger of a wholly-owned subsidiary of the Company with and into Progenics in which Progenics stockholders will receive, for each share of Progenics stock held at the time of the closing of the Progenics Transaction, merger consideration consisting of 0.31 of a share of the Company’s common stock and a non-tradeable contingent value right (a “CVR”) tied to the financial performance of PyL^TM (¹⁸F-DCFPyL), Progenics’ prostate-specific membrane antigen targeted imaging agent designed to visualize prostate cancer currently in late stage clinical development (“PyL”). Each CVR will entitle its holder to receive a pro rata share of aggregate cash payments equal to 40% of U.S. net sales generated by PyL in 2022 and 2023 in excess of $100 million and $150 million, respectively. In no event will the Company’s aggregate payments in respect of the CVRs, together with any other non-stock consideration treated as paid in connection with the Progenics Transaction, exceed 19.9% of the total consideration the Company pays in the Progenics Transaction. Following the closing of the Progenics Transaction, the aggregate ownership stake of the former Progenics stockholders will be approximately 40% of the combined company. Progenics’ stockholders will also be entitled to appraisal rights as provided under Delaware law. In addition, pursuant to the Amended Merger Agreement, the holder of each in-the-money option to purchase shares of Progenics common stock under any equity based compensation plan of Progenics (“Progenics Stock Option”) will be entitled to receive in exchange for each such in-the-money option (i) an option to purchase common stock of the Company (each, a “Company Stock Option”) converted based on the 0.31 exchange ratio and (ii) a vested or unvested CVR depending on whether the underlying option is vested. Holders of out-of-the-money Progenics Stock Options will receive Company Stock Options converted on an exchange ratio adjusted based on actual trading prices of common stock of Progenics and the Company prior to the closing of the Progenics Transaction. The Progenics Transaction was unanimously approved by the Boards of Directors of both companies and requires, among other things, the affirmative vote of a majority of the outstanding shares of common stock of Progenics and a majority of votes cast by the holders of the common stock of the Company. The Progenics Transaction is currently expected to close in June 2020, subject to the satisfaction or waiver of certain closing conditions. Following the closing of the Progenics Transaction, which the parties intend to report as tax-deferred to Progenics’ stockholders with respect to the stock component of the merger consideration for U.S. federal income tax purposes, the combined company will continue to be headquartered in North Billerica, Massachusetts and will trade on the NASDAQ under the ticker symbol LNTH. On March 15, 2020, Progenics and LMI entered into a bridge loan agreement, pursuant to which LMI agreed to provide for a secured short-term loan to Progenics on or after May 1, 2020 in an aggregate principal amount of up to $10.0 million. The bridge loan matures on the earlier to occur of (a) September 30, 2020 and (b) the date on which Progenics enters into a debt financing or similar arrangements or any amendment to, or replacement of, its existing debt provided by one or more third parties following the termination date of the merger agreement, in either case, having aggregate net cash proceeds that exceed the amount then required to repay all obligations under the bridge loan agreement in full in cash. The bridge loan bears interest at a rate per annum of 9.5% and is secured through the pledge to LMI of all of the issued and outstanding shares of capital stock of Molecular Insight Pharmaceuticals, Inc., a subsidiary of Progenics (“MIPI”), and any debt of MIPI owed to Progenics. COVID-19 On March 11, 2020, the World Health Organization declared the novel coronavirus (“COVID-19”), a respiratory illness first identified in Wuhan, China, a pandemic. The global spread of COVID-19 has created significant volatility, uncertainty and economic disruption. Governments in affected regions have implemented, and may continue to implement, safety precautions which include quarantines, travel restrictions, business closures, cancellations of public gatherings and other measures as they deem necessary. Many organizations and individuals, including the Company and its employees, are taking additional steps to avoid or reduce infection, including limiting travel and working from home. These measures are disrupting normal business operations both in and outside of affected areas and have had significant negative impacts on businesses and financial markets worldwide. The Company experienced operational and financial impacts from the COVID-19 pandemic beginning late in the first quarter of 2020, including the impact of stay-at-home mandates and related safety measures such as the delay of elective medical procedures, resulting in a decline in the volume of procedures using the Company’s products. As a result of the COVID-19 pandemic, the Company undertook a thorough analysis of all of its discretionary expenses. In the first quarter of 2020, the Company implemented certain cost reduction initiatives, including, among other things, reducing travel and promotional expenses and implementing a hiring freeze through the balance of 2020. The severity of the material impact of the COVID-19 pandemic on the Company's business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company's customers and suppliers, all of which are uncertain and cannot be predicted. While the impact of COVID-19 on the Company’s results of operations and cash flows is expected to be material, at least in the short term, given the dynamic nature of this situation, the Company is currently unable to accurately predict the impact of COVID-19 on its overall 2020 operations and financial results or cash flows for the foreseeable future and whether the impact of COVID-19 could lead to potential impairments.

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Derivative Instruments

The Company uses interest rate swaps to reduce the variability in cash flows associated with a portion of the Company’s forecasted interest payments on its variable rate debt. To qualify for hedge accounting, the hedging instrument must be highly effective at reducing the risk from the exposure being hedged. Further, the Company must formally document the hedging relationship at inception and, on at least a quarterly basis, continually reevaluate the relationship to ensure it remains highly effective throughout the life of the hedge. The Company does not enter into derivative financial instruments for speculative or trading purposes.

Recent Accounting Pronouncements



Standard	Description	Effective Date for Company	Effect on the Condensed Consolidated Financial Statements
Recently Issued Accounting Standards Not Yet Adopted
ASU 2020-04, “Reference Rate Reform (Topic 848)”	This ASU provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting.	March 12, 2020 through December 31, 2022	The Company does not expect that the adoption of this standard will have a material impact on the Company’s condensed consolidated financial statements.
Accounting Standards Adopted During the Three Months Ended March 31, 2020
ASU 2016-13, “Financial Instruments-Credit Losses (Topic 326)”	This ASU will require financial instruments measured at amortized cost and accounts receivable to be presented at the net amount expected to be collected. The new model requires an entity to estimate credit losses based on historical information, current information and reasonable and supportable forecasts that affect the collectability of the reported amount.	January 1, 2020	The adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.

Revenue from Contracts with Customers

3 Months Ended

Mar. 31, 2020

Revenue from Contract with Customer [Abstract]

Revenue from Contracts with Customers

The following table summarizes revenue by revenue source and reportable segment as follows:



	Three Months Ended March 31,
Major Products/Service Lines by Segment (in thousands)	2020		2019
U.S.
Product revenue, net⁽¹⁾	$	78,745	$	75,434
Total U.S. revenues	78,745		75,434
International
Product revenue, net⁽¹⁾	11,468		10,549
License and royalty revenues	491		527
Total International revenues	11,959		11,076
Total revenues	$	90,704	$	86,510

________________________________


(1)	The Company’s principal products include DEFINITY and TechneLite and are categorized within product revenue, net. The Company applies the

same revenue recognition policies and judgments for all of its principal products.

The Company’s performance obligations are typically part of contracts that have an original expected duration of one year or less. As such, the Company is not disclosing the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied (or partially satisfied) as of the end of the reporting period.

Fair Value of Financial Instruments

3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability of fair value measurements, financial instruments are categorized based on a hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:


•	Level 1 — Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

•

Level 2 — Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.) and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).


•	Level 3 — Unobservable inputs that reflect a Company’s estimates about the assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available, including its own data.

The Company’s financial assets measured at fair value on a recurring basis consist of money market funds and interest rate swaps. The Company invests excess cash from its operating cash accounts in overnight investments and reflects these amounts in cash and cash equivalents in the condensed consolidated balance sheets at fair value using quoted prices in active markets for identical assets. The fair value of the interest rate swaps are determined based on observable market-based inputs, including interest rate curves and reflects the contractual terms of these instruments, including the period to maturity. Please refer to Note 10, “Derivative Instruments”, for further details on the interest rate swaps.

The tables below present information about the Company’s assets and liabilities measured at fair value on a recurring basis:



	March 31, 2020
(in thousands)	Total Fair Value		Level 1		Level 2		Level 3
Money market	$	42,051	$	42,051	$	—	$	—
Interest rate swaps	1,330		—		1,330		—
Total	$	43,381	$	42,051	$	1,330	$	—



	December 31, 2019
(in thousands)	Total Fair Value		Level 1		Level 2		Level 3
Money market	$	39,530	$	39,530	$	—	$	—
Total	$	39,530	$	39,530	$	—	$	—

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Income Taxes

3 Months Ended

Mar. 31, 2020

Income Tax Disclosure [Abstract]

Income Taxes

The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full year, adjusted for any discrete events which are recorded in the period they occur. The Company’s effective tax rate in fiscal 2020 differs from the U.S. federal statutory rate of 21% principally due to the impact of state taxes and the accrual of interest on uncertain tax positions. Cumulative adjustments to the tax provision are recorded in the interim period in which a change in the estimated annual effective tax rate is determined. The Company’s income tax expense is presented below:



	Three Months Ended March 31,
(in thousands)	2020		2019
Income tax expense	$	2,192	$	2,815

The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realizability of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more-likely-than-not realizable, the Company evaluated all available positive and negative evidence, and weighed the objective evidence and expected impact. The Company continues to record a valuation allowance of $1.2 million against the net deferred tax assets of its U.K. subsidiary.

In connection with the Company’s acquisition of the medical imaging business from Bristol-Myers Squibb (“BMS”) in 2008, the Company recorded a liability for uncertain tax positions related to the acquired business and simultaneously entered into a tax indemnification agreement with BMS under which BMS agreed to indemnify the Company for any payments made to settle those uncertain tax positions with the taxing authorities. Accordingly, a long-term receivable is recorded to account for the expected value to the Company of future indemnification payments, net of actual tax benefits received, to be paid on behalf of the Company by BMS. The tax indemnification receivable is recorded within other long-term assets.

In accordance with the Company’s accounting policy, the change in the tax liability, penalties and interest associated with these obligations (net of any offsetting federal or state benefit) is recognized within income tax expense. As these reserves change, adjustments are included in income tax expense while the offsetting adjustment is included in other income. Assuming that the receivable from BMS continues to be considered recoverable by the Company, there will be no effect on net income and no net cash outflows related to these liabilities.

Inventory

3 Months Ended

Mar. 31, 2020

Inventory Disclosure [Abstract]

Inventory

Inventory consisted of the following:



(in thousands)	March 31, 2020		December 31, 2019
Raw materials	$	11,607	$	11,417
Work in process	12,445		9,450
Finished goods	6,762		8,313
Total inventory	$	30,814	$	29,180

Property, Plant and Equipment, Net

3 Months Ended

Mar. 31, 2020

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment, Net

Property, plant and equipment, net, consisted of the following:



(in thousands)	March 31, 2020			December 31, 2019
Land	$	13,450		$	13,450
Buildings	69,622			75,654
Machinery, equipment and fixtures	76,251			87,763
Computer software	20,768			20,739
Construction in progress	11,165			10,546
	191,256			208,152
Less: accumulated depreciation and amortization	(82,643		)	(91,655		)
Total property, plant and equipment, net	$	108,613		$	116,497

Depreciation and amortization expense related to property, plant and equipment, net, was $3.0 million and $2.5 million for the three months ended March 31, 2020 and 2019, respectively.

The Company tests long-lived assets for recoverability whenever events or changes in circumstances suggest that the carrying value of an asset or group of assets may not be recoverable. As a result of a decline in expected future cash flows and the effect of COVID-19 related to certain other nuclear legacy manufacturing assets in the U.S. segment, the Company determined certain impairment triggers had occurred. Accordingly, the Company performed an undiscounted cash flow analysis as of March 31, 2020. Based on the undiscounted cash flow analysis, the Company determined that the manufacturing assets had net carrying values that exceeded their estimated undiscounted future cash flows. The Company then estimated the fair values of the asset group based on their discounted cash flows. The carrying value exceeded the fair value and as a result, the Company recorded a non-cash impairment of $7.3 million for the three months ended March 31, 2020 in cost of goods sold in the condensed consolidated statement of operations.

Asset Retirement Obligations

3 Months Ended

Mar. 31, 2020

Asset Retirement Obligation Disclosure [Abstract]

Asset Retirement Obligations

The Company considers its legal obligation to remediate its facilities upon a decommissioning of its radioactive-related operations as an asset retirement obligation. The Company has production facilities which manufacture and process radioactive materials at its North Billerica, Massachusetts and San Juan, Puerto Rico sites. As of March 31, 2020, the liability is measured at the present value of the obligation expected to be incurred, of approximately $26.9 million.

The following table provides a summary of the changes in the Company’s asset retirement obligations:



(in thousands)	Amount
Balance at January 1, 2020	$	12,883
Accretion expense	360
Balance at March 31, 2020	$	13,243

The Company is required to provide the U.S. Nuclear Regulatory Commission and Massachusetts Department of Public Health financial assurance demonstrating the Company’s ability to fund the decommissioning of its North Billerica, Massachusetts production facility upon closure, although the Company does not intend to close the facility. The Company has provided this financial assurance in the form of a $28.2 million surety bond.

Long-Term Debt, Net, and Other Borrowings

3 Months Ended

Mar. 31, 2020

Debt Disclosure [Abstract]

Long-Term Debt, Net, and Other Borrowings

As of March 31, 2020, the Company’s maturities of principal obligations under its long-term debt and other borrowings are as follows:



(in thousands)	Amount
Remainder of 2020	$	7,500
2021	10,000
2022	11,250
2023	15,000
2024	148,750
Total principal outstanding	192,500
Unamortized debt discount	(458		)
Unamortized debt issuance costs	(730		)
Finance lease liabilities	319
Total	191,631
Less: current portion	(10,143		)
Total long-term debt, net and other borrowings	$	181,488

At March 31, 2020, the Company’s interest rate under the 2019 Term Facility was 2.5%.

Derivative Instruments

3 Months Ended

Mar. 31, 2020

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments

The Company uses interest rate swaps to reduce the variability in cash flows associated with a portion of the Company’s forecasted interest payments on its variable rate debt. In March 2020, the Company entered into interest rate swap contracts to fix the LIBOR rate on a notional amount of $100.0 million through May 31, 2024. This agreement involves the receipt of floating rate amounts in exchange for fixed rate interest payments over the life of the agreement without an exchange of the underlying principal amount. The interest rate swaps were designated as cash flow hedges. In accordance with hedge accounting, the interest rate swaps are recorded on the Company’s condensed consolidated balance sheets at fair value, and changes in the fair value of the swap agreements are recorded to other comprehensive loss and reclassified to interest expense in the period during which the hedged transaction affected earnings or it will become probable that the forecasted transaction would not occur. At March 31, 2020, accumulated other comprehensive loss included $0.4 million of pre-tax deferred losses that are expected to be reclassified to earnings during the next 12 months.

The following table presents the location and fair value amounts of derivative instruments reported in the condensed consolidated balance sheet:



(in thousands)		March 31, 2020		December 31, 2019
Derivatives type	Classification
Liabilities:
Interest rate swap	Accrued expenses and other liabilities	$	1,330	$	—

Accumulated Other Comprehensive Loss

3 Months Ended

Mar. 31, 2020

Equity [Abstract]

Accumulated Other Comprehensive Loss

The components of Accumulated Other Comprehensive Loss, net of tax of $0.3 million and $0.0 million for the three months ended March 31, 2020 and March 31, 2019, respectively, consisted of the following:



(in thousands)	Foreign currency translation			Unrealized loss on cash flow hedges			Accumulated other comprehensive loss
Balance at January 1, 2020	$	(960	)	$	—		$	(960	)
Other comprehensive loss before reclassifications	(446		)	(988		)	(1,434		)
Amounts reclassified to earnings	—			—			—
Balance at March 31, 2020	$	(1,406	)	$	(988	)	$	(2,394	)

Balance at January 1, 2019	$	(1,108	)	$	—		$	(1,108	)
Other comprehensive income before reclassifications	56			—			56
Amounts reclassified to earnings	—			—			—
Balance at March 31, 2019	$	(1,052	)	$	—		$	(1,052	)

Stock-Based Compensation

3 Months Ended

Mar. 31, 2020

Share-based Payment Arrangement [Abstract]

Stock-Based Compensation

The following table presents stock-based compensation expense recognized in the Company’s accompanying condensed consolidated statements of operations:



	Three Months Ended March 31,
(in thousands)	2020		2019
Cost of goods sold	$	618	$	440
Sales and marketing	253		451
General and administrative	1,815		1,574
Research and development	389		255
Total stock-based compensation expense	$	3,075	$	2,720

Net Income Per Common Share

3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Net Income Per Common Share

A summary of net income per common share is presented below:



	Three Months Ended March 31,
(in thousands, except per share amounts)	2020		2019
Net income	$	3,337	$	9,949

Basic weighted-average common shares outstanding	39,433		38,603
Effect of dilutive stock options	28		58
Effect of dilutive restricted stock	641		1,126
Diluted weighted-average common shares outstanding	40,102		39,787

Basic income per common share	$	0.08	$	0.26
Diluted income per common share	$	0.08	$	0.25

Antidilutive securities excluded from diluted net income per common share	604		222

Other Income

3 Months Ended

Mar. 31, 2020

Other Income and Expenses [Abstract]

Other Income

Other income consisted of the following:



	Three Months Ended March 31,
(in thousands)	2020			2019
Foreign currency (losses) gains	$	(314	)	$	42
Tax indemnification income, net	555			802
Interest income	109			283
Other	—			60
Total other income	$	350		$	1,187

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	and Contingencies Legal Proceedings From time to time, the Company is a party to various legal proceedings arising in the ordinary course of business. In addition, the Company has in the past been, and may in the future be, subject to investigations by governmental and regulatory authorities, which expose it to greater risks associated with litigation, regulatory or other proceedings, as a result of which the Company could be required to pay significant fines or penalties. The costs and outcome of litigation, regulatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company and could have a material adverse effect on the Company’s results of operations or financial condition. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. As of March 31, 2020, the Company had no material ongoing litigation in which the Company was a party. In addition, the Company had no material ongoing regulatory or other proceedings and no knowledge of any investigations by government or regulatory authorities in which the Company is a target, in either case, that the Company believes could have a material and adverse effect on its current business.

Segment Information

3 Months Ended

Mar. 31, 2020

Segment Reporting [Abstract]

Segment Information

The Company reports two operating segments, U.S. and International, based on geographic customer base. The results of these operating segments are regularly reviewed by the Company’s chief operating decision maker, the President and Chief Executive Officer. The Company’s segments derive revenues through the manufacture, marketing, selling and distribution of medical imaging products, focused primarily on cardiovascular diagnostic imaging. All goodwill has been allocated to the U.S. operating segment. The Company does not identify or allocate assets to its segments.

Selected information regarding the Company’s segments is provided as follows:



	Three Months Ended March 31,
(in thousands)	2020			2019
Revenue by product from external customers
U.S.
DEFINITY	$	55,010		$	49,716
TechneLite	19,356			20,058
Other nuclear	9,062			9,524
Rebates and allowances	(4,683		)	(3,864		)
Total U.S. Revenues	78,745			75,434
International
DEFINITY	1,781			1,395
TechneLite	3,742			4,087
Other nuclear	6,438			5,596
Rebates and allowances	(2		)	(2		)
Total International Revenues	11,959			11,076
Worldwide
DEFINITY	56,791			51,111
TechneLite	23,098			24,145
Other nuclear	15,500			15,120
Rebates and allowances	(4,685		)	(3,866		)
Total Revenues	$	90,704		$	86,510



	Three Months Ended March 31,
(in thousands)	2020			2019
Operating income
U.S.	$	4,988		$	14,584
International	2,137			1,585
Total operating income	7,125			16,169
Interest expense	1,946			4,592
Other income	(350		)	(1,187		)
Income before income taxes	$	5,529		$	12,764

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On April 1, 2020, the Company drew down $100.0 million under its 2019 Revolving Facility, the proceeds of which the Company has currently invested in short-term, interest-bearing instruments. On April 2, 2020, the Company and Progenics issued a joint press release announcing that they had decided to reschedule their respective special meetings of stockholders to vote on matters related to the Progenics Transaction from April 28, 2020 to June 16, 2020. The rescheduled special meetings will allow both companies the time necessary to respond to the COVID-19 pandemic and its effect on each company’s business and on the combined entity and provide appropriate disclosure to their shareholders. The Company is continuing to monitor the latest developments regarding the COVID-19 pandemic and its impact on the Company’s business, financial condition, results of operations and prospects. On April 10, 2020, the Company announced several steps that it has taken to respond to the COVID-19 pandemic intended to maintain financial flexibility. These actions include transitioning to a four day work week to better align manufacturing, supply, distribution and other activities with reduced product demand, reducing non-essential discretionary expenses, and reducing executive and employee compensation effective April 13, 2020 for the balance of the second quarter of 2020. In addition, our Board of Directors has also reduced director and committee member compensation by 35% for the second half of the year and has elected to receive all remaining compensation payable in 2020 in the form of time-based restricted stock units that will vest on the first anniversary of the grant date, rather than in cash. On April 14, 2020, the Company entered into a support agreement (the “Support Agreement”) with Velan Capital, L.P., Altiva Management Inc., Velan Capital Partners LP, Velan Capital Holdings LLC, Velan Capital Investment Management LP, Velan Principals GP LLC, Velan Capital Management LLC, Balaji Venkataraman, Deepak Sarpangal and Kevin McNeill (collectively, the “Velan Stockholders”), pursuant to which, among other things and subject to the terms and conditions set forth in the Support Agreement, the Velan Stockholders agreed to vote (or cause to be voted) their respective shares of Company and Progenics common stock in favor of certain matters relating to the Progenics Transaction, and that the Velan Stockholders will abide by certain customary standstill provisions, in each case, subject to the terms and conditions set forth in the Support Agreement.

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Derivative Instruments

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements include the accounts of Lantheus Holdings, Inc. and its direct and indirect wholly-owned subsidiaries and have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all of the information and notes required by generally accepted accounting principles in the United States of America (“U.S. GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement have been included. The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results that may be expected for the year ended December 31, 2020 or any future period.

The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date but does not include all of the information and notes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities Exchange Commission (“SEC”) on February 25, 2020.

Recent Accounting Pronouncements



Standard	Description	Effective Date for Company	Effect on the Condensed Consolidated Financial Statements
Recently Issued Accounting Standards Not Yet Adopted
ASU 2020-04, “Reference Rate Reform (Topic 848)”	This ASU provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting.	March 12, 2020 through December 31, 2022	The Company does not expect that the adoption of this standard will have a material impact on the Company’s condensed consolidated financial statements.
Accounting Standards Adopted During the Three Months Ended March 31, 2020
ASU 2016-13, “Financial Instruments-Credit Losses (Topic 326)”	This ASU will require financial instruments measured at amortized cost and accounts receivable to be presented at the net amount expected to be collected. The new model requires an entity to estimate credit losses based on historical information, current information and reasonable and supportable forecasts that affect the collectability of the reported amount.	January 1, 2020	The adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Recent Accounting Pronouncements



Standard	Description	Effective Date for Company	Effect on the Condensed Consolidated Financial Statements
Recently Issued Accounting Standards Not Yet Adopted
ASU 2020-04, “Reference Rate Reform (Topic 848)”	This ASU provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting.	March 12, 2020 through December 31, 2022	The Company does not expect that the adoption of this standard will have a material impact on the Company’s condensed consolidated financial statements.
Accounting Standards Adopted During the Three Months Ended March 31, 2020
ASU 2016-13, “Financial Instruments-Credit Losses (Topic 326)”	This ASU will require financial instruments measured at amortized cost and accounts receivable to be presented at the net amount expected to be collected. The new model requires an entity to estimate credit losses based on historical information, current information and reasonable and supportable forecasts that affect the collectability of the reported amount.	January 1, 2020	The adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.

Revenue from Contracts with Customers (Tables)

3 Months Ended

Mar. 31, 2020

Revenue from Contract with Customer [Abstract]

Schedule of disaggregation of revenue

The following table summarizes revenue by revenue source and reportable segment as follows:



	Three Months Ended March 31,
Major Products/Service Lines by Segment (in thousands)	2020		2019
U.S.
Product revenue, net⁽¹⁾	$	78,745	$	75,434
Total U.S. revenues	78,745		75,434
International
Product revenue, net⁽¹⁾	11,468		10,549
License and royalty revenues	491		527
Total International revenues	11,959		11,076
Total revenues	$	90,704	$	86,510

________________________________


(1)	The Company’s principal products include DEFINITY and TechneLite and are categorized within product revenue, net. The Company applies the

same revenue recognition policies and judgments for all of its principal products.

Fair Value of Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Schedule of assets and liabilities measured at fair value on a recurring basis

The tables below present information about the Company’s assets and liabilities measured at fair value on a recurring basis:



	March 31, 2020
(in thousands)	Total Fair Value		Level 1		Level 2		Level 3
Money market	$	42,051	$	42,051	$	—	$	—
Interest rate swaps	1,330		—		1,330		—
Total	$	43,381	$	42,051	$	1,330	$	—



	December 31, 2019
(in thousands)	Total Fair Value		Level 1		Level 2		Level 3
Money market	$	39,530	$	39,530	$	—	$	—
Total	$	39,530	$	39,530	$	—	$	—

Income Taxes (Tables)

3 Months Ended

Mar. 31, 2020

Income Tax Disclosure [Abstract]

Schedule of income tax expense

The Company’s income tax expense is presented below:



	Three Months Ended March 31,
(in thousands)	2020		2019
Income tax expense	$	2,192	$	2,815

Inventory (Tables)

3 Months Ended

Mar. 31, 2020

Inventory Disclosure [Abstract]

Schedule of inventory

Inventory consisted of the following:



(in thousands)	March 31, 2020		December 31, 2019
Raw materials	$	11,607	$	11,417
Work in process	12,445		9,450
Finished goods	6,762		8,313
Total inventory	$	30,814	$	29,180

Property, Plant and Equipment, Net (Tables)

3 Months Ended

Mar. 31, 2020

Property, Plant and Equipment [Abstract]

Schedule of property, plant, and equipment, net

Property, plant and equipment, net, consisted of the following:



(in thousands)	March 31, 2020			December 31, 2019
Land	$	13,450		$	13,450
Buildings	69,622			75,654
Machinery, equipment and fixtures	76,251			87,763
Computer software	20,768			20,739
Construction in progress	11,165			10,546
	191,256			208,152
Less: accumulated depreciation and amortization	(82,643		)	(91,655		)
Total property, plant and equipment, net	$	108,613		$	116,497

Asset Retirement Obligations (Tables)

3 Months Ended

Mar. 31, 2020

Asset Retirement Obligation Disclosure [Abstract]

Summary of changes in asset retirement obligations

The following table provides a summary of the changes in the Company’s asset retirement obligations:



(in thousands)	Amount
Balance at January 1, 2020	$	12,883
Accretion expense	360
Balance at March 31, 2020	$	13,243

Long-Term Debt, Net, and Other Borrowings (Tables)

3 Months Ended

Mar. 31, 2020

Debt Disclosure [Abstract]

Schedule of maturities of principal obligations

As of March 31, 2020, the Company’s maturities of principal obligations under its long-term debt and other borrowings are as follows:



(in thousands)	Amount
Remainder of 2020	$	7,500
2021	10,000
2022	11,250
2023	15,000
2024	148,750
Total principal outstanding	192,500
Unamortized debt discount	(458		)
Unamortized debt issuance costs	(730		)
Finance lease liabilities	319
Total	191,631
Less: current portion	(10,143		)
Total long-term debt, net and other borrowings	$	181,488

Derivative Instruments (Tables)

3 Months Ended

Mar. 31, 2020

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Instruments

The following table presents the location and fair value amounts of derivative instruments reported in the condensed consolidated balance sheet:



(in thousands)		March 31, 2020		December 31, 2019
Derivatives type	Classification
Liabilities:
Interest rate swap	Accrued expenses and other liabilities	$	1,330	$	—

Accumulated Other Comprehensive Loss (Tables)

3 Months Ended

Mar. 31, 2020

Equity [Abstract]

Schedule of Accumulated Other Comprehensive Income



(in thousands)	Foreign currency translation			Unrealized loss on cash flow hedges			Accumulated other comprehensive loss
Balance at January 1, 2020	$	(960	)	$	—		$	(960	)
Other comprehensive loss before reclassifications	(446		)	(988		)	(1,434		)
Amounts reclassified to earnings	—			—			—
Balance at March 31, 2020	$	(1,406	)	$	(988	)	$	(2,394	)

Balance at January 1, 2019	$	(1,108	)	$	—		$	(1,108	)
Other comprehensive income before reclassifications	56			—			56
Amounts reclassified to earnings	—			—			—
Balance at March 31, 2019	$	(1,052	)	$	—		$	(1,052	)

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2020

Share-based Payment Arrangement [Abstract]

Schedule of stock-based compensation expense recognized

The following table presents stock-based compensation expense recognized in the Company’s accompanying condensed consolidated statements of operations:



	Three Months Ended March 31,
(in thousands)	2020		2019
Cost of goods sold	$	618	$	440
Sales and marketing	253		451
General and administrative	1,815		1,574
Research and development	389		255
Total stock-based compensation expense	$	3,075	$	2,720

Net Income Per Common Share (Tables)

3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Summary of net income per common share

A summary of net income per common share is presented below:



	Three Months Ended March 31,
(in thousands, except per share amounts)	2020		2019
Net income	$	3,337	$	9,949

Basic weighted-average common shares outstanding	39,433		38,603
Effect of dilutive stock options	28		58
Effect of dilutive restricted stock	641		1,126
Diluted weighted-average common shares outstanding	40,102		39,787

Basic income per common share	$	0.08	$	0.26
Diluted income per common share	$	0.08	$	0.25

Antidilutive securities excluded from diluted net income per common share	604		222

Other Income (Tables)

3 Months Ended

Mar. 31, 2020

Other Income and Expenses [Abstract]

Schedule of other income

Other income consisted of the following:



	Three Months Ended March 31,
(in thousands)	2020			2019
Foreign currency (losses) gains	$	(314	)	$	42
Tax indemnification income, net	555			802
Interest income	109			283
Other	—			60
Total other income	$	350		$	1,187

Segment Information (Tables)

3 Months Ended

Mar. 31, 2020

Segment Reporting [Abstract]

Schedule of segment information

Selected information regarding the Company’s segments is provided as follows:



	Three Months Ended March 31,
(in thousands)	2020			2019
Revenue by product from external customers
U.S.
DEFINITY	$	55,010		$	49,716
TechneLite	19,356			20,058
Other nuclear	9,062			9,524
Rebates and allowances	(4,683		)	(3,864		)
Total U.S. Revenues	78,745			75,434
International
DEFINITY	1,781			1,395
TechneLite	3,742			4,087
Other nuclear	6,438			5,596
Rebates and allowances	(2		)	(2		)
Total International Revenues	11,959			11,076
Worldwide
DEFINITY	56,791			51,111
TechneLite	23,098			24,145
Other nuclear	15,500			15,120
Rebates and allowances	(4,685		)	(3,866		)
Total Revenues	$	90,704		$	86,510



	Three Months Ended March 31,
(in thousands)	2020			2019
Operating income
U.S.	$	4,988		$	14,584
International	2,137			1,585
Total operating income	7,125			16,169
Interest expense	1,946			4,592
Other income	(350		)	(1,187		)
Income before income taxes	$	5,529		$	12,764

Basis of Presentation (Details) - USD ($)	Feb. 20, 2020	Mar. 15, 2020
Progenics Pharmaceuticals Inc
Business Acquisition [Line Items]
Shares to be received from acquisition conversion (in shares)	0.31
Percentage of net sales, contingent consideration	40.00%
Percentage of total contingent consideration under CVRs	19.90%
Percentage of acquired interest	40.00%
Cash Payments 2022 \| Progenics Pharmaceuticals Inc
Business Acquisition [Line Items]
Contingent consideration value	$ 100,000,000
Cash Payments 2023 \| Progenics Pharmaceuticals Inc
Business Acquisition [Line Items]
Contingent consideration value	$ 150,000,000
Bridge Loan \| Progenics Pharmaceuticals Inc
Business Acquisition [Line Items]
Debt, face amount		$ 10,000,000.0
Debt, stated interest rate		9.50%

Revenue from Contracts with Customers (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Disaggregation of Revenue [Line Items]
Revenues	$ 90,704	$ 86,510
U.S.
Disaggregation of Revenue [Line Items]
Revenues	78,745	75,434
U.S. \| Product revenue, net
Disaggregation of Revenue [Line Items]
Revenues	78,745	75,434
International
Disaggregation of Revenue [Line Items]
Revenues	11,959	11,076
International \| Product revenue, net
Disaggregation of Revenue [Line Items]
Revenues	11,468	10,549
International \| License and royalty revenues
Disaggregation of Revenue [Line Items]
Revenues	$ 491	$ 527

Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market	$ 42,051	$ 39,530
Interest rate swaps	1,330
Total	43,381	39,530
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market	42,051	39,530
Interest rate swaps	0
Total	42,051	39,530
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market	0	0
Interest rate swaps	1,330
Total	1,330	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market	0	0
Interest rate swaps	0
Total	$ 0	$ 0

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Income tax expense	$ 2,192	$ 2,815
Deferred tax asset, valuation allowance	$ 1,200

Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 11,607	$ 11,417
Work in process	12,445	9,450
Finished goods	6,762	8,313
Total inventory	$ 30,814	$ 29,180

Property, Plant and Equipment, Net (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Property, Plant & Equipment [Line Items]
Property, plant & equipment, gross	$ 191,256		$ 208,152
Less: accumulated depreciation and amortization	(82,643)		(91,655)
Total property, plant and equipment, net	108,613		116,497
Depreciation and amortization expense	3,000	$ 2,500
Impairment of long-lived assets	7,275	$ 0
Land
Property, Plant & Equipment [Line Items]
Property, plant & equipment, gross	13,450		13,450
Buildings
Property, Plant & Equipment [Line Items]
Property, plant & equipment, gross	69,622		75,654
Machinery, equipment and fixtures
Property, Plant & Equipment [Line Items]
Property, plant & equipment, gross	76,251		87,763
Computer software
Property, Plant & Equipment [Line Items]
Property, plant & equipment, gross	20,768		20,739
Construction in progress
Property, Plant & Equipment [Line Items]
Property, plant & equipment, gross	$ 11,165		$ 10,546

Asset Retirement Obligations (Details) $ in Thousands	3 Months Ended
Asset Retirement Obligations (Details) $ in Thousands	Mar. 31, 2020 USD ($)
Asset Retirement Obligation Disclosure [Abstract]
Asset retirement obligation liabilities expected, present value	$ 26,900
Financial assurance in form of surety bond	28,200
Asset Retirement Obligation, Roll Forward Analysis [Roll Forward]
Asset retirement obligations, beginning balance	12,883
Accretion expense	360
Asset retirement obligations, ending balance	$ 13,243

Long-Term Debt, Net, and Other Borrowings (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
Remainder of 2020	$ 7,500
2021	10,000
2022	11,250
2023	15,000
2024	148,750
Total principal outstanding	192,500
Unamortized debt discount	(458)
Unamortized debt issuance costs	(730)
Finance lease liabilities	319
Total	191,631
Less: current portion	(10,143)	$ (10,143)
Total long-term debt, net and other borrowings	$ 181,488	$ 183,927
2019 Facility
Debt Instrument [Line Items]
Interest rate under long-term debt	2.50%

Derivative Instruments (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Derivative [Line Items]
Pre-tax deferred losses expected to be reclassified to earnings during the next 12 months	$ 400,000
Cash Flow Hedge \| Interest Rate Swaps
Derivative [Line Items]
Notional amount	100,000,000.0
Cash Flow Hedge \| Interest Rate Swaps \| Accrued expenses and other liabilities
Derivative [Line Items]
Liabilities	$ 1,330,000	$ 0

Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss, tax	$ 300	$ 0
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	114,601	71,002
Other comprehensive loss before reclassifications	(1,434)	56
Amounts reclassified to earnings	0	0
Ending balance	118,398	83,213
Foreign currency translation
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(960)	(1,108)
Other comprehensive loss before reclassifications	(446)	56
Amounts reclassified to earnings	0	0
Ending balance	(1,406)	(1,052)
Unrealized loss on cash flow hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	0	0
Other comprehensive loss before reclassifications	(988)	0
Amounts reclassified to earnings	0	0
Ending balance	(988)	0
Accumulated Other Comprehensive Loss
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(960)	(1,108)
Ending balance	$ (2,394)	$ (1,052)

Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended
Stock-Based Compensation (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 3,075	$ 2,720
Cost of goods sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	618	440
Sales and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	253	451
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	1,815	1,574
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 389	$ 255

Net Income Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Net income	$ 3,337	$ 9,949
Basic weighted-average common shares outstanding (in shares)	39,433	38,603
Effect of dilutive stock options (in shares)	28	58
Effect of dilutive restricted stock (in shares)	641	1,126
Diluted weighted-average common shares outstanding (in shares)	40,102	39,787
Basic income per common share (in dollars per share)	$ 0.08	$ 0.26
Diluted income per common share (in dollars per share)	$ 0.08	$ 0.25
Antidilutive securities excluded from diluted net income per common share (in shares)	604	222

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

+ Details

Other Income (Details) - USD ($) $ in Thousands	3 Months Ended
Other Income (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Mar. 31, 2019
Other Income and Expenses [Abstract]
Foreign currency (losses) gains	$ (314)	$ 42
Tax indemnification income, net	555	802
Interest income	109	283
Other	0	60
Total other income	$ 350	$ 1,187

Segment Information (Details) $ in Thousands	3 Months Ended
Segment Information (Details) $ in Thousands	Mar. 31, 2020 USD ($) segment	Mar. 31, 2019 USD ($)
Segment Reporting [Abstract]
Number of operating segments \| segment	2
Geographical revenues
Revenues	$ 90,704	$ 86,510
Operating income	7,125	16,169
Interest expense	1,946	4,592
Other income	(350)	(1,187)
Income before income taxes	5,529	12,764
DEFINITY
Geographical revenues
Revenues	56,791	51,111
TechneLite
Geographical revenues
Revenues	23,098	24,145
Other nuclear
Geographical revenues
Revenues	15,500	15,120
Rebates and allowances
Geographical revenues
Revenues	4,685	3,866
U.S.
Geographical revenues
Revenues	78,745	75,434
Operating income	4,988	14,584
U.S. \| DEFINITY
Geographical revenues
Revenues	55,010	49,716
U.S. \| TechneLite
Geographical revenues
Revenues	19,356	20,058
U.S. \| Other nuclear
Geographical revenues
Revenues	9,062	9,524
U.S. \| Rebates and allowances
Geographical revenues
Revenues	4,683	3,864
International
Geographical revenues
Revenues	11,959	11,076
Operating income	2,137	1,585
International \| DEFINITY
Geographical revenues
Revenues	1,781	1,395
International \| TechneLite
Geographical revenues
Revenues	3,742	4,087
International \| Other nuclear
Geographical revenues
Revenues	6,438	5,596
International \| Rebates and allowances
Geographical revenues
Revenues	$ 2	$ 2

Subsequent Events (Details) - Subsequent Event - USD ($) $ in Millions	Apr. 01, 2020	Apr. 10, 2020
Subsequent Event [Line Items]
Proceeds from line of credit	$ 100.0
Director and committee member compensation reduction		35.00%